TSW
ACOR

Thompson Siegel & Walmsley’s Acorda Therapeutics ACOR Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,906
Closed -$22.3M – 697
2014
Q1 		$22.3M Sell
4,906
-3,865
-44% -$15.6M 0.5% 60
2013
Q4 		$30.7M Buy
8,771
+2,102
+32% +$8.2M 0.72% 26
2013
Q3 		$27.4M Sell
6,669
-363
-5% -$1.56M 0.59% 42
2013
Q2 		$27.8M Buy
+7,032
New +$29M 0.6% 39

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Thompson Siegel & Walmsley's ACOR Position: Q2 2014 in Review

Thompson Siegel & Walmsley sold out of Acorda Therapeutics (ACOR) in Q2 2014, closing a stake of 4,906 shares — an estimated $22.3M sold.

Thompson Siegel & Walmsley first reported a position in ACOR in Q2 2013 and held it in 4 quarters. The position peaked at $30.7M in Q4 2013. 162 funds tracked by Wall St. Rank hold ACOR as of Q2 2014.

  • Thompson Siegel & Walmsley reported no remaining Acorda Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 4,906 Acorda Therapeutics shares in Q2 2014, an estimated $22.3M.
  • Thompson Siegel & Walmsley first reported a position in Acorda Therapeutics in Q2 2013 and held it in 4 quarters.
  • Thompson Siegel & Walmsley's Acorda Therapeutics position peaked at $30.7M in Q4 2013.
  • 162 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2014.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2014, filed 12 Aug 2014.